AnaptysBio Inc. (ANAB)

41.21
NASDAQ : Health Technology
Prev Close 41.75
Day Low/High 40.70 / 42.30
52 Wk Low/High 38.53 / 110.00
Avg Volume 308.00K
Exchange NASDAQ
Shares Outstanding 27.05M
Market Cap 1.13B
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

AnaptysBio To Present At The Wedbush PacGrow 2019 Healthcare Conference

AnaptysBio To Present At The Wedbush PacGrow 2019 Healthcare Conference

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc.

First Week Of ANAB February 2020 Options Trading

First Week Of ANAB February 2020 Options Trading

Investors in AnaptysBio Inc saw new options begin trading this week, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APPF, BLBD, BOJA, EROS, GAIA, ICD, LOB, TLRA, WMIH, XL, Y Downgrades: CLD, FUL, GOV, HZN, KOSS, NAP, OKE, STN Initiations: ANAB Read on to get TheStreet Quant Ratings' detailed report:

ANAB Crosses Above Average Analyst Target

ANAB Crosses Above Average Analyst Target

In recent trading, shares of AnaptysBio Inc have crossed above the average analyst 12-month target price of $82.71, changing hands for $84.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

AnaptysBio Announces First Quarter 2017 Financial Results And Provides Pipeline Update

Top-line Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017

AnaptysBio Announces First-In-Human Dosing Of ANB019

Novel Anti-IL-36 Receptor Antibody for the Treatment of Severe Orphan Inflammatory Disorders

AnaptysBio Announces 2016 Operating Results And Pipeline Progress

Data from Ongoing ANB020 Phase 2a Trials and ANB019 Phase 1 Trial Expected in Second Half 2017

AnaptysBio Announces Data From Scientific Collaboration With The Benaroya Research Institute Presented At The AAAAI 2017 Annual Meeting

Data Support Rationale for Development of AnaptysBio's Anti-IL-33 Antibody, ANB020, for the Treatment of Severe Adult Peanut Allergy

TheStreet Quant Rating: D (Sell)